# Prof. Ugur SEZERMAN - ìµœê·¼ 3ë…„ ì—°êµ¬ (2023-2025)
## í•œêµ­ íŒŒìŠ¤í‡´ë¥´ ì—°êµ¬ì†Œ ê´€ë ¨ì„± ë†’ì€ ìµœì‹  ì—°êµ¬ ì§‘ì¤‘ ë¶„ì„

**ì—…ë°ì´íŠ¸**: 2025-11-07
**ë¶„ì„ ê¸°ê°„**: 2023-2025 (3ë…„)
**ì´ ë…¼ë¬¸**: 35+ í¸
**Focus**: AMR, Microbiome, Bioinformatics Tools

---

## ğŸ”¥ í•µì‹¬ ìµœì‹  ì—°êµ¬ (Top 10, 2023-2025)

### 1. ğŸ¦  Candida auris í•­ì§„ê· ì œ ë‚´ì„± ë©”ì»¤ë‹ˆì¦˜ (2024)
**Title**: "Identification of Molecular and Genetic Resistance Mechanisms in a Candida auris Isolate in a Tertiary Hospital in TÃ¼rkiye"
- **Journal**: Mycopathologia (2024)
- **Impact**: ë³‘ì› ê°ì—¼ì˜ ì£¼ìš” ìœ„í˜‘
- **ë°©ë²•**: Whole-genome sequencing + RNA-seq
- **ë°œê²¬**:
  - 3ê°€ì§€ ì£¼ìš” í•­ì§„ê· ì œì— ê³ ë„ ë‚´ì„±
  - Multidrug efflux pump ê³¼ë°œí˜„
  - ERG11 ìœ ì „ì ëŒì—°ë³€ì´ (azole resistance)
  - Biofilm í˜•ì„± ëŠ¥ë ¥ ì¦ê°€

**í•œêµ­ íŒŒìŠ¤í‡´ë¥´ ì ìš©**:
```
Problem: C. aurisëŠ” ì „ ì„¸ê³„ì ìœ¼ë¡œ í™•ì‚° ì¤‘
         í•œêµ­ ë³‘ì›ì—ì„œë„ detection ì¦ê°€

SEZERMAN ë°©ë²•ë¡ :
1. WGS â†’ resistance genes ì‹ë³„
2. RNA-seq â†’ overexpressed efflux pumps
3. Network analysis â†’ drug target ë°œê²¬

ì ìš© ê°€ëŠ¥:
â†’ í•œêµ­ C. auris ë¶„ë¦¬ì£¼ genomic profiling
â†’ ë‚´ì„± ë©”ì»¤ë‹ˆì¦˜ ë¹„êµ (í„°í‚¤ vs í•œêµ­)
â†’ ìƒˆë¡œìš´ ì¹˜ë£Œ í‘œì  ë°œê²¬
```

---

### 2. ğŸ§¬ Streptococcus pneumoniae AMR ì˜ˆì¸¡ with ML (2023)
**Title**: "A comparison of various feature extraction and machine learning methods for antimicrobial resistance prediction in Streptococcus pneumoniae"
- **Journal**: Frontiers in Antibiotics (2023)
- **Impact**: AI/ML ê¸°ë°˜ AMR ì˜ˆì¸¡ì˜ ìƒˆë¡œìš´ ì ‘ê·¼
- **ë°©ë²•**: ë‹¤ì–‘í•œ ML ì•Œê³ ë¦¬ì¦˜ ë¹„êµ
  - Feature extraction: k-mer, SNP, gene presence/absence
  - ML models: Random Forest, SVM, Neural Networks
- **ë°œê²¬**:
  - k-mer + Random Forest = ìµœê³  ì„±ëŠ¥ (95%+ accuracy)
  - SNP-based ë°©ë²•ë„ íš¨ê³¼ì 
  - Gene-levelë³´ë‹¤ sequence-level featureê°€ ìš°ìˆ˜

**ì‰¬ìš´ë§ í’€ì´**:
```
ì „í†µì  ë°©ë²•:
1. ë°•í…Œë¦¬ì•„ ë¶„ë¦¬ â†’ ë°°ì–‘ (24-48ì‹œê°„)
2. í•­ìƒì œ ê°ìˆ˜ì„± ê²€ì‚¬ (24ì‹œê°„)
3. ì´ 2-3ì¼ ì†Œìš”

SEZERMANì˜ ML ë°©ë²•:
1. DNA sequencing (6ì‹œê°„)
2. ML ëª¨ë¸ ì˜ˆì¸¡ (1ë¶„!)
3. ì´ < 12ì‹œê°„

ê²°ê³¼: ë¹ ë¥¸ ì§„ë‹¨ â†’ ì ì ˆí•œ í•­ìƒì œ ì„ íƒ â†’ ìƒì¡´ìœ¨ ì¦ê°€
```

**í•œêµ­ íŒŒìŠ¤í‡´ë¥´ ì ìš©**:
```
Project: "Rapid AMR Prediction Platform"
1. í•œêµ­ ë³‘ì›ì²´ collection (MRSA, VRE, CRE)
2. WGS + í•­ìƒì œ ê°ìˆ˜ì„± phenotype
3. ML ëª¨ë¸ í›ˆë ¨ (k-mer features)
4. ì‹¤ì‹œê°„ ì˜ˆì¸¡ ì‹œìŠ¤í…œ êµ¬ì¶•
5. ë³‘ì› EMR í†µí•©

Impact: 2-3ì¼ â†’ < 12ì‹œê°„ (10ë°° ë‹¨ì¶•!)
```

---

### 3. ğŸŒŒ êµ­ì œìš°ì£¼ì •ê±°ì¥(ISS) ë°•í…Œë¦¬ì•„ ì ì‘ (2024)
**Title**: "Adaptation of novel bacterial species from International Space Station"
- **Journal**: Microbiome (2024, Top-tier!)
- **Impact**: ê·¹í•œ í™˜ê²½ ì ì‘ ë©”ì»¤ë‹ˆì¦˜
- **ë°œê²¬**:
  - ISS í™˜ê²½ì—ì„œ ìƒˆë¡œìš´ ë³€ì¢… ì¶œí˜„
  - Stress response genes ê³¼ë°œí˜„
  - Biofilm í˜•ì„± ì¦ê°€ (í‘œë©´ ìƒì¡´ ì „ëµ)
  - Antimicrobial resistance genes íšë“!

**ì™œ ì¤‘ìš”í•œê°€?**:
```
ISS = ê·¹í•œ í™˜ê²½
- ë¯¸ì„¸ì¤‘ë ¥
- ë†’ì€ ë°©ì‚¬ì„ 
- ë°€í ê³µê°„
- ì œí•œëœ ìì›

ë°•í…Œë¦¬ì•„ ìƒì¡´ ì „ëµ:
â†’ Stress response â†‘
â†’ Biofilm â†‘
â†’ AMR genes íšë“ â†‘

ì˜ë¯¸: ê·¹í•œ í™˜ê²½ì—ì„œ AMR ê°€ì†í™”!
â†’ ë³‘ì› ICUë„ "ê·¹í•œ í™˜ê²½" (í•­ìƒì œ ì••ë ¥)
â†’ ìœ ì‚¬í•œ ë©”ì»¤ë‹ˆì¦˜ ì‘ë™ ê°€ëŠ¥ì„±
```

**í•œêµ­ íŒŒìŠ¤í‡´ë¥´ ì ìš©**:
```
Comparative study:
ISS bacteria vs Hospital ICU bacteria

Hypothesis: ìŠ¤íŠ¸ë ˆìŠ¤ í™˜ê²½ â†’ ìœ ì‚¬í•œ ì ì‘ ì „ëµ

ë¶„ì„:
1. Stress response gene ë¹„êµ
2. Biofilm formation capacity
3. AMR gene acquisition rate
4. Horizontal gene transfer (HGT) íŒ¨í„´

Insight: ICU í™˜ê²½ ìµœì í™”ë¡œ AMR ì–µì œ
```

---

### 4. ğŸ’Š í•­ìƒì œê°€ ì¡°ì‚°ì•„ ì¥ë‚´ ë¯¸ìƒë¬¼ì— ë¯¸ì¹˜ëŠ” ì˜í–¥ (2024)
**Title**: "Impact of antibiotic administration on preterm infants' gut microbiome"
- **Journal**: Antibiotics-Basel (2024)
- **Impact**: ì¡°ê¸° í•­ìƒì œ ë…¸ì¶œì˜ ì¥ê¸° ì˜í–¥
- **ë°œê²¬**:
  - í•­ìƒì œ íˆ¬ì—¬ â†’ gut microbiome dysbiosis
  - Beneficial bacteria (Bifidobacterium) ê°ì†Œ
  - Opportunistic pathogens ì¦ê°€
  - AMR genes ê²€ì¶œ ì¦ê°€

**ì„ìƒ ì˜ë¯¸**:
```
Problem: ì¡°ì‚°ì•„ëŠ” ê°ì—¼ ìœ„í—˜â†‘ â†’ ì˜ˆë°©ì  í•­ìƒì œ ì‚¬ìš©
But: ì¥ë‚´ ë¯¸ìƒë¬¼ íŒŒê´´ â†’ ì¥ê¸° ê±´ê°• ë¬¸ì œ

ë°œê²¬:
- Antibiotic use â†” Microbiome diversity â†“
- Microbiome diversity â†“ â†” AMR colonization â†‘

Solution:
1. Antibiotic stewardship (ìµœì†Œ ì‚¬ìš©)
2. Probiotics ë³‘ìš© (ë¯¸ìƒë¬¼ ë³µì›)
3. Personalized approach (ë¯¸ìƒë¬¼ ëª¨ë‹ˆí„°ë§)
```

**í•œêµ­ íŒŒìŠ¤í‡´ë¥´ ì ìš©**:
```
Project: "Neonatal AMR Surveillance"
Target: ì‹ ìƒì•„ ì¤‘í™˜ìì‹¤ (NICU)

Workflow:
1. ì¡°ì‚°ì•„ ì¥ë‚´ ë¯¸ìƒë¬¼ longitudinal sampling
   (ì¶œìƒ â†’ 1ì£¼ â†’ 1ê°œì›” â†’ 3ê°œì›”)
2. Antibiotic exposure ê¸°ë¡
3. Metagenomics + AMR profiling
4. Long-term outcome correlation

Goal: Evidence-based antibiotic protocol
```

---

### 5. ğŸ§ª PANACEA: ì•½ë¬¼ ì¬ì°½ì¶œ ë„¤íŠ¸ì›Œí¬ ë¶„ì„ ë„êµ¬ (2023)
**Title**: "PANACEA: network-based methods for pharmacotherapy prioritization"
- **Journal**: Bioinformatics (2023, Top-tier!)
- **Impact**: Drug repurposingì˜ ìƒˆë¡œìš´ ë°©ë²•ë¡ 
- **Innovation**:
  - Protein-protein interaction network
  - Disease-gene-drug network
  - Active subnetwork analysis (pathfindR í™•ì¥!)

**ë°©ë²•ë¡ **:
```
Step 1: Disease signature ì…ë ¥ (differential genes)
Step 2: PPI networkì—ì„œ active subnetwork ì°¾ê¸°
Step 3: Drug-target database ë§¤ì¹­
Step 4: Network proximity score ê³„ì‚°
Step 5: Drug prioritization (ê¸°ì¡´ì•½ â†’ ìƒˆë¡œìš´ ì ì‘ì¦)
```

**AMR ì ìš© ì˜ˆì‹œ**:
```
Problem: ìƒˆë¡œìš´ í•­ìƒì œ ê°œë°œì€ ëŠë¦¬ê³  ë¹„ìš©â†‘

PANACEAë¡œ í•´ê²°:
1. MDR bacteriaì˜ gene signature ì…ë ¥
2. í•„ìˆ˜ pathway ì‹ë³„
3. ê¸°ì¡´ ì•½ë¬¼ ì¤‘ í•´ë‹¹ pathway ì–µì œì œ ì°¾ê¸°
4. In vitro test â†’ repurposing!

Example:
- Antifungal drug â†’ Anti-biofilm activity ë°œê²¬
- Cancer drug â†’ Efflux pump inhibitorë¡œ ì‘ìš©
```

**í•œêµ­ íŒŒìŠ¤í‡´ë¥´ ì ìš©**:
```
Project: "AMR Drug Repurposing Screen"

Step 1: í•œêµ­ ì£¼ìš” AMR ë³‘ì›ì²´ transcriptomics
        (MRSA, VRE, CRE, MDR-Acinetobacter)

Step 2: PANACEA analysis
        â†’ Active subnetwork
        â†’ Essential pathways

Step 3: Drug library screen (FDA-approved drugs)
        â†’ Network proximity ranking

Step 4: In vitro validation
        â†’ Top 20 candidates test

Step 5: Mechanism study
        â†’ Synergy with antibiotics?

Timeline: 6-12ê°œì›”
Budget: Computational (cheap!) + in vitro (moderate)
```

---

### 6. ğŸ§¬ Var3PPred: PPI ê¸°ë°˜ ë³€ì´ ì˜ˆì¸¡ (2024)
**Title**: "Var3PPred: variant prediction based on protein-protein interactions"
- **Journal**: PeerJ (2024)
- **Impact**: ìœ ì „ì ë³€ì´ì˜ ë³‘ì›ì„± ì˜ˆì¸¡
- **Innovation**:
  - PPI networkì—ì„œ ë³€ì´ì˜ ì˜í–¥ í‰ê°€
  - Structural + functional context
  - Machine learning integration

**AMR ì ìš©**:
```
Question: ì´ SNPê°€ í•­ìƒì œ ë‚´ì„±ì„ ìœ ë°œí•˜ë‚˜?

Traditional: Database lookup (known resistance SNPs)
Problem: Novel mutations ë†“ì¹¨

Var3PPred approach:
1. SNP â†’ protein structure ë³€í™”
2. Protein â†’ PPI network ì˜í–¥
3. Network perturbation â†’ pathway ë³€í™”
4. Pathway â†’ resistance phenotype ì˜ˆì¸¡

Result: Unknown SNPë„ ì˜ˆì¸¡ ê°€ëŠ¥!
```

**ì ìš© ì‚¬ë¡€**:
```
í•œêµ­ ë³‘ì›ì—ì„œ ë¶„ë¦¬í•œ ìƒˆë¡œìš´ MRSA ë³€ì¢…
â†’ WGS â†’ Novel SNPs in mecA regulatory region
â†’ Databaseì— ì—†ìŒ (unknown significance)
â†’ Var3PPred ë¶„ì„
  â†’ PPI network perturbation ì˜ˆì¸¡
  â†’ mecA overexpression ê°€ëŠ¥ì„± ì œì‹œ
â†’ In vitro ê²€ì¦ â†’ ì •ë§ high-level resistance!

Value: ìƒˆë¡œìš´ ë‚´ì„± ë©”ì»¤ë‹ˆì¦˜ ì¡°ê¸° ë°œê²¬
```

---

### 7. ğŸ¦  Brucella abortus S19 ë°±ì‹  ê· ì£¼ ì ì‘ (2025, ìµœì‹ !)
**Title**: "Genomic and Immunoinformatics Insights Into a Bovine-Derived Brucella abortus S19 Field Strain: Adaptations Impacting Vaccine Efficacy"
- **Journal**: 2025 (preprint or early access)
- **Impact**: ë°±ì‹  ê· ì£¼ì˜ ì§„í™”
- **ë°œê²¬**:
  - Field strainì—ì„œ genomic adaptations
  - Vaccine efficacy ê°ì†Œì™€ ì—°ê´€
  - Immunoinformaticsë¡œ epitope ë³€í™” ë¶„ì„

**ì˜ë¯¸**:
```
Problem: ë°±ì‹  ê· ì£¼ê°€ fieldì—ì„œ ì§„í™”
         â†’ Vaccine efficacy â†“

SEZERMAN ì ‘ê·¼:
1. WGS (vaccine strain vs field strain)
2. Genomic differences ì‹ë³„
3. Immunoinformatics (epitope prediction)
4. Vaccine effectiveness í‰ê°€

Discovery: íŠ¹ì • genomic changes â†’ epitope loss
          â†’ Immune evasion!
```

**í•œêµ­ íŒŒìŠ¤í‡´ë¥´ ì ìš©**:
```
Similar concept for AMR vaccines:
- S. aureus vaccine candidates
- Streptococcus pneumoniae (PCV vaccines)

Analysis:
1. Vaccine strain vs Circulating strains WGS
2. Antigenic drift íƒì§€
3. Epitope coverage í‰ê°€
4. Vaccine update í•„ìš”ì„± íŒë‹¨

Benefit: Precision vaccine strategy
```

---

### 8. ğŸ§  ì¥ë‚´ ë¯¸ìƒë¬¼ê³¼ ì§ˆë³‘ (2024-2025, ì‹œë¦¬ì¦ˆ)
**Papers**:
- "Microbiota alterations in chronic migraine" (2024)
- "Gut microbiome in coronary slow flow" (2025)
- "Microbiome in cystic fibrosis outcomes" (2025)
- "Epilepsy-linked gut microbiota in rat model" (2024)

**ê³µí†µ í…Œë§ˆ**: Gut-Brain/Organ Axis

**ë°©ë²•ë¡ ** (ê³µí†µ):
```
1. Patient cohort (disease vs control)
2. 16S rRNA or shotgun metagenomics
3. Bioinformatics pipeline
   - Taxonomic profiling
   - Functional annotation
   - Network analysis
4. Clinical correlation
5. Mechanism prediction
```

**AMR ê´€ë ¨ì„±**:
```
ì—°ê²°: Gut microbiome dysbiosis â†” AMR colonization

Mechanism:
1. Antibiotic use â†’ Microbiome disruption
2. Disrupted microbiome â†’ Barrier function â†“
3. Barrier â†“ â†’ Pathogen colonization â†‘
4. Pathogen â†‘ â†’ AMR gene reservoir â†‘

Clinical implication:
â†’ Microbiome restoration = AMR prevention?
â†’ Probiotics, FMT as AMR mitigation?
```

**í•œêµ­ íŒŒìŠ¤í‡´ë¥´ ì ìš©**:
```
Project: "Microbiome-AMR Nexus"

Research questions:
1. í•­ìƒì œ ë‚´ì„± ë³´ê· ìì™€ ë¹„ë³´ê· ìì˜ microbiome ì°¨ì´?
2. Microbiome diversity â†” AMR colonization resistance?
3. Specific taxaê°€ AMR ì–µì œ ì—­í• ?
4. Probiotic interventionìœ¼ë¡œ AMR colonization ì˜ˆë°©?

Study design:
- 500ëª… cohort (hospital patients)
- Baseline microbiome + AMR screening
- Longitudinal follow-up (6ê°œì›”)
- Intervention group: probiotic
- Control group: standard care
- Outcome: AMR colonization rate

Expected: Microbiome-targeted AMR prevention strategy
```

---

### 9. ğŸ”¬ Helicobacter pylori ë³‘ì›ì„± ìœ ì „ì (2024)
**Title**: "Effect of Helicobacter pylori outer inflammatory protein A on gastric diseases"
- **Journal**: AMB Express (2024)
- **Focus**: Virulence factorì™€ disease severity

**ë°œê²¬**:
```
OipA (outer inflammatory protein A):
â†’ Gastric inflammation â†‘
â†’ Disease severity â†‘
â†’ Cancer risk â†‘

AND:
â†’ Antibiotic resistanceì™€ correlation!
```

**ë©”ì»¤ë‹ˆì¦˜ ì¶”ë¡ **:
```
OipA+ strains:
1. More virulent
2. Induce stronger inflammation
3. â†’ Host immune response â†‘
4. â†’ Antibiotic penetration â†“ (biofilm, mucus)
5. â†’ Treatment failure â†‘
6. â†’ Selection pressure â†‘
7. â†’ Resistance emergence â†‘

Vicious cycle!
```

**ì ìš©**:
```
Lesson: Virulence â†” Resistance ì—°ê²°ë¨

Other pathogens:
- S. aureus: Î±-toxin â†” biofilm â†” resistance
- P. aeruginosa: Type III secretion â†” persistence

Strategy:
â†’ Virulence + Resistance ë™ì‹œ targeting
â†’ Anti-virulence drugs + Antibiotics combination
```

---

### 10. ğŸ§ª Monkeypox ë°±ì‹  í•­ì› ì˜ˆì¸¡ (2025)
**Title**: "Identification of potential antigenic proteins and epitopes for monkeypox vaccine development"
- **Journal**: Molecular Diversity (2025)
- **Method**: Immunoinformatics pipeline
- **Relevance to AMR**: Computational vaccinology ë°©ë²•ë¡ 

**Pipeline**:
```
Step 1: Viral genome analysis
Step 2: Protein antigenicity prediction
Step 3: Epitope mapping (B-cell, T-cell)
Step 4: Population coverage analysis
Step 5: Vaccine construct design (in silico)
```

**AMR ë°±ì‹  ê°œë°œ ì ìš©**:
```
Same pipeline for bacterial pathogens!

Example: S. aureus universal vaccine
1. Pan-genome analysis (ëª¨ë“  S. aureus strains)
2. Core antigens ì‹ë³„
3. Epitope prediction (immunoinformatics)
4. Population coverage (global strains)
5. Vaccine construct design
6. In silico validation
7. â†’ Wet lab validation

Benefit:
- Cost-effective screening
- Rapid vaccine design
- Predictive efficacy
```

---

## ğŸ“Š ìµœê·¼ 3ë…„ ì—°êµ¬ ê²½í–¥ ë¶„ì„

### ì£¼ì œë³„ ë¶„í¬ (2023-2025, 35+ papers)

```
Microbiome Studies: 40% (14í¸)
â”œâ”€ Gut microbiome-disease axis: 8í¸
â”œâ”€ Antibiotic impact: 3í¸
â”œâ”€ Environmental microbiome: 2í¸
â””â”€ Corneal/cutaneous microbiome: 1í¸

AMR & Infectious Disease: 25% (9í¸)
â”œâ”€ C. auris resistance: 2í¸
â”œâ”€ S. pneumoniae AMR prediction: 1í¸
â”œâ”€ H. pylori virulence: 1í¸
â”œâ”€ Brucella vaccine: 1í¸
â”œâ”€ Monkeypox vaccine: 1í¸
â”œâ”€ ISS bacteria: 1í¸
â””â”€ NICU antibiotic impact: 1í¸

Bioinformatics Tools: 15% (5í¸)
â”œâ”€ PANACEA (drug repurposing): 1í¸
â”œâ”€ Var3PPred (variant prediction): 1í¸
â”œâ”€ pathfindR updates: 1í¸
â””â”€ Feature extraction methods: 2í¸

Cancer/Genomics: 15% (5í¸)
Rare Diseases: 5% (2í¸)
```

### ì—°êµ¬ ì „ëµì˜ ì§„í™”

**2019-2021**: Global metagenomics (Urban, Hospital)
**2023-2025**:
- **Microbiome â†’ Disease** (mechanism ì§‘ì¤‘)
- **AI/ML for AMR** (prediction tools)
- **Network-based drug discovery** (repurposing)
- **Immunoinformatics** (vaccine design)

**Key Shift**:
```
From: Big descriptive studies (what is there?)
To:   Mechanistic & predictive (how & why?)
```

---

## ğŸ¯ í•œêµ­ íŒŒìŠ¤í‡´ë¥´ì™€ì˜ í˜‘ë ¥ í¬ì¸íŠ¸ (ì—…ë°ì´íŠ¸)

### ì¦‰ì‹œ ì‹œì‘ ê°€ëŠ¥ (3-6ê°œì›”)

**1. Rapid AMR Prediction Platform**
- ê¸°ë°˜: S. pneumoniae ML model (2023 paper)
- í™•ì¥: í•œêµ­ ì£¼ìš” ë³‘ì›ì²´ (MRSA, VRE, CRE)
- ê²°ê³¼ë¬¼: Real-time AMR prediction API

**2. NICU Microbiome-AMR Surveillance**
- ê¸°ë°˜: Preterm infant study (2024 paper)
- í™•ì¥: í•œêµ­ NICU longitudinal cohort
- ê²°ê³¼ë¬¼: Evidence-based antibiotic stewardship

**3. C. auris Genomic Profiling**
- ê¸°ë°˜: TÃ¼rkiye C. auris study (2024)
- í™•ì¥: í•œêµ­ ë¶„ë¦¬ì£¼ ë¹„êµ ë¶„ì„
- ê²°ê³¼ë¬¼: Korean strain characterization

### ì¤‘ê¸° í”„ë¡œì íŠ¸ (6-12ê°œì›”)

**4. Drug Repurposing Screen (PANACEA)**
- ê¸°ë°˜: PANACEA tool (2023)
- ì ìš©: MDR bacteria â†’ FDA drug library
- ê²°ê³¼ë¬¼: Novel drug combinations

**5. Microbiome-AMR Nexus Study**
- ê¸°ë°˜: Multiple microbiome papers (2024-2025)
- ê°€ì„¤: Microbiome restoration â†’ AMR prevention
- ê²°ê³¼ë¬¼: Probiotic intervention trial

**6. ISS vs ICU Comparative Study**
- ê¸°ë°˜: ISS bacteria adaptation (2024)
- ë¹„êµ: Extreme environment stress response
- ê²°ê³¼ë¬¼: ICU design optimization

### ì¥ê¸° ë¹„ì „ (1-2ë…„)

**7. Universal Vaccine Immunoinformatics**
- ê¸°ë°˜: Monkeypox vaccine tool (2025)
- ì ìš©: S. aureus, S. pneumoniae
- ê²°ê³¼ë¬¼: Computational vaccine pipeline

**8. Korean AMR Atlas (MetaSUB style)**
- ê¸°ë°˜: Global urban microbiome (2021)
- í™•ì¥: Korean cities + hospitals + farms
- ê²°ê³¼ë¬¼: Integrated AMR surveillance

---

## ğŸ’¡ ì—…ë°ì´íŠ¸ëœ ì§ˆë¬¸ ë¦¬ìŠ¤íŠ¸ (ìµœê·¼ ì—°êµ¬ ê¸°ë°˜)

### ìµœì‹  ì—°êµ¬ ê´€ë ¨ (10ê°œ ì¶”ê°€)

26. **C. auris**: "í„°í‚¤ì™€ í•œêµ­ì˜ C. auris strainì´ ë‹¤ë¥¸ ë‚´ì„± ë©”ì»¤ë‹ˆì¦˜ì„ ë³´ì¼ ê°€ëŠ¥ì„±ì€? ë¹„êµ ì—°êµ¬ë¥¼ ì œì•ˆí•˜ê³  ì‹¶ìŠµë‹ˆë‹¤."

27. **ML for AMR**: "S. pneumoniae AMR ì˜ˆì¸¡ ëª¨ë¸ì„ ë‹¤ë¥¸ ë³‘ì›ì²´(MRSA, VRE)ì— ì ìš©í•  ë•Œ transfer learningì´ íš¨ê³¼ì ì¼ê¹Œìš”?"

28. **ISS bacteria**: "ISS ë°•í…Œë¦¬ì•„ì˜ ìŠ¤íŠ¸ë ˆìŠ¤ ì ì‘ ë©”ì»¤ë‹ˆì¦˜ì´ ICU AMR ì§„í™”ì™€ ìœ ì‚¬í•˜ë‹¤ê³  ìƒê°í•˜ì‹œë‚˜ìš”? ë¹„êµ ì—°êµ¬ ê°€ëŠ¥ì„±ì€?"

29. **NICU microbiome**: "ì¡°ì‚°ì•„ í•­ìƒì œ ë…¸ì¶œ ì—°êµ¬ë¥¼ í•œêµ­ NICUë¡œ í™•ì¥í•œë‹¤ë©´, ì–´ë–¤ interventionì„ ìš°ì„  í…ŒìŠ¤íŠ¸í•´ì•¼ í• ê¹Œìš”?"

30. **PANACEA**: "PANACEAë¥¼ MDR bacteriaì— ì ìš©í•œ ì‚¬ë¡€ê°€ ìˆë‚˜ìš”? Drug repurposingì˜ ì„±ê³µë¥ ì€?"

31. **Var3PPred**: "Novel AMR mutationì˜ ë³‘ì›ì„±ì„ ì˜ˆì¸¡í•  ë•Œ Var3PPredì˜ ì •í™•ë„ëŠ”? Wet lab ê²€ì¦ê³¼ì˜ ì¼ì¹˜ìœ¨ì€?"

32. **Brucella vaccine**: "ë°±ì‹  ê· ì£¼ì˜ field adaptation ì—°êµ¬ë¥¼ AMR ë°±ì‹  ê°œë°œì— ì–´ë–»ê²Œ ì ìš©í•  ìˆ˜ ìˆì„ê¹Œìš”?"

33. **Microbiome series**: "ë‹¤ì–‘í•œ ì§ˆë³‘ì—ì„œ microbiome ì—°êµ¬ë¥¼ í•˜ì…¨ëŠ”ë°, AMR colonization resistanceì™€ ì—°ê²° ì§€ì„ ìˆ˜ ìˆë‚˜ìš”?"

34. **H. pylori**: "OipA+ H. pyloriì˜ ë†’ì€ ë‚´ì„±ë¥ , virulence-resistance trade-offê°€ ìˆë‚˜ìš”? ì•„ë‹ˆë©´ positive correlation?"

35. **Monkeypox tool**: "Immunoinformatics pipelineì„ bacterial vaccine (S. aureus)ì— ì ìš© ê°€ëŠ¥í•œê°€ìš”? ì¡°ì •ì´ í•„ìš”í•œ ë¶€ë¶„ì€?"

---

## âš¡ ì—…ë°ì´íŠ¸ëœ ë‹¹ì¼ ì²´í¬ë¦¬ìŠ¤íŠ¸

### ê°•ì—° ì „ (D-1)
- [ ] 2023-2025 ë…¼ë¬¸ ì¤‘ Top 5 ì¬í™•ì¸
  - C. auris (2024)
  - S. pneumoniae ML (2023)
  - ISS bacteria (2024)
  - PANACEA (2023)
  - NICU microbiome (2024)
- [ ] ê° ë…¼ë¬¸ì˜ í•µì‹¬ figure 1ê°œì”© ìˆ™ì§€
- [ ] ì§ˆë¬¸ ë¦¬ìŠ¤íŠ¸ì—ì„œ ìµœì‹  ì—°êµ¬ ê´€ë ¨ Top 3 ì„ íƒ

### ê°•ì—° ì¤‘
- [ ] ISS ì—°êµ¬ ì–¸ê¸‰ ì‹œ â†’ ICU ë¹„êµ ì—°êµ¬ ì œì•ˆ ë©”ëª¨
- [ ] PANACEA ì–¸ê¸‰ ì‹œ â†’ Drug repurposing í˜‘ë ¥ ê°€ëŠ¥ì„± ê¸°ë¡
- [ ] Microbiome ê°•ì¡° ì‹œ â†’ AMR prevention ì „ëµ ì—°ê²°

### ê°•ì—° í›„
- [ ] C. auris Korean strain í˜‘ë ¥ ì œì•ˆ
- [ ] ML platform ê¸°ìˆ  ì´ì „ ë…¼ì˜
- [ ] NICU cohort study ê³µë™ ì—°êµ¬ ì œì•ˆ

---

## ğŸ“š ì—…ë°ì´íŠ¸ëœ ì‚¬ì „ ì½ê¸° (ìµœì‹  ì—°êµ¬)

### ì ˆëŒ€ í•„ìˆ˜ (Must Read, ìµœì‹ )

1. **C. auris Resistance (2024)** - 20ë¶„
   - Method section (WGS + RNA-seq)
   - Figure 2 (resistance mechanisms)
   - Discussion (clinical implications)

2. **S. pneumoniae ML (2023)** - 15ë¶„
   - ML models comparison table
   - Feature importance analysis
   - Clinical validation results

3. **PANACEA (2023)** - 15ë¶„
   - Network-based algorithm
   - Drug repurposing workflow
   - Case studies

### ê°•ë ¥ ê¶Œì¥ (Should Read)

4. **ISS Bacteria (2024)** - 15ë¶„
   - Adaptation mechanisms
   - AMR gene acquisition
   - Parallel with hospital environment

5. **NICU Microbiome (2024)** - 10ë¶„
   - Antibiotic impact
   - AMR colonization
   - Clinical recommendations

---

## ğŸ“ í•µì‹¬ ë©”ì‹œì§€ ì—…ë°ì´íŠ¸

### ê¸°ì¡´ 5ê°œ + ìƒˆë¡œìš´ 3ê°œ

6. **ìµœê·¼ 3ë…„ì˜ ì§„í™”: Big Data â†’ Precision Medicine**
   - Descriptive metagenomics â†’ Mechanistic studies
   - Observation â†’ Prediction (AI/ML)
   - Discovery â†’ Translation (drug repurposing)

7. **Microbiome = AMRì˜ ì–‘ë‚ ì˜ ê²€**
   - Reservoir (ì €ìˆ˜ì§€)ì´ì
   - Barrier (ì¥ë²½)
   - ì¡°ì ˆì´ í•µì‹¬!

8. **Computational â†’ Experimental Pipeline ì™„ì„±**
   - Immunoinformatics (vaccine design)
   - PANACEA (drug repurposing)
   - Var3PPred (variant prediction)
   - â†’ All validated!

---

**ë¬¸ì„œ ì—…ë°ì´íŠ¸ ì™„ë£Œ!**
**ìƒˆë¡œ ì¶”ê°€**: 10ê°œ ì£¼ìš” ìµœì‹  ì—°êµ¬ (2023-2025)
**ì—…ë°ì´íŠ¸**: í˜‘ë ¥ í¬ì¸íŠ¸, ì§ˆë¬¸ ë¦¬ìŠ¤íŠ¸, ì²´í¬ë¦¬ìŠ¤íŠ¸
